Loading organizations...
Key people at Bryn Pharma.
Founded in 2016 by Michelle Lobel and Steven Hartman, Bryn Pharma is a privately held pharmaceutical company based in Raleigh, North Carolina, that develops a needleless epinephrine nasal spray for the emergency treatment of anaphylaxis. The enterprise operates within the severe allergy treatment sector, aiming to disrupt the traditional autoinjector market by providing an accessible alternative designed specifically for patients and caregivers managing dangerous allergic reactions. The company's executive leadership includes current Chief Executive Officer Sandy Loreaux, who was appointed in March 2023 to succeed former chief executive David Dworaczyk. Operating at the Series E stage, the organization has secured $125.2 million in total venture capital funding to support the clinical development and commercialization of its pharmaceutical products. This capitalization includes a recent $15 million financing round that followed a previous $26.72 million capital injection.
Key people at Bryn Pharma.
Bryn Pharma is a clinical-stage pharmaceutical company developing a needle-free epinephrine nasal spray for emergency treatment of anaphylaxis, targeting patients with severe allergies who struggle with traditional injectors.[1][2][6] Formerly known as Epi-Now, the company serves individuals at risk of life-threatening allergic reactions, addressing key problems like needle phobia, ease of use, portability, and affordability in epinephrine delivery.[1][2] Founded in 2016 (with some sources noting 2017), it has raised $125.2M in funding, reaching Series E stage, with its latest round of $26.72M about a year ago, signaling strong growth momentum toward commercialization.[1][3]
Headquartered in Raleigh, North Carolina, Bryn Pharma has demonstrated product viability through studies showing efficacy even with nasal congestion and holds 10 patents, including on epinephrine spray formulations.[1]
Bryn Pharma emerged from a patient-driven mission to improve anaphylaxis management, founded in 2016 as Epi-Now by individuals motivated by personal experiences with allergies—explicitly "founded by patients for patients."[1][2] The idea stemmed from decades-old limitations in epinephrine autoinjectors, prompting development of a nasal spray alternative using advanced science and patented technologies.[2]
Early traction included pharmacokinetic studies published around 2020 and patent grants, such as one in 2023 for epinephrine spray formulations related to allergology and sympathetic nervous systems.[1][4] Key leadership hires, like a former COO from Aerami Therapeutics, bolstered clinical and regulatory progress for its lead asset, NDS1C.[2] Investors like Blue Cloud Ventures supported its evolution to Series E.[1]
Bryn Pharma rides the wave of innovative drug delivery in allergy care, capitalizing on rising anaphylaxis prevalence amid growing food allergy awareness and demand for user-friendly alternatives to EpiPens.[1][2] Timing aligns with recent FDA nods to nasal epinephrine options, filling unmet needs in a large, expanding market stagnant for decades.[2]
Market forces like patient non-adherence to injectors (due to complexity and phobia) favor its approach, while its inhaled platform hints at broader applications beyond anaphylaxis.[5] By prioritizing accessibility, it influences pharma ecosystems, potentially lowering barriers for at-risk populations and spurring competition in acute care delivery.[2]
Bryn Pharma nears pivotal regulatory milestones for NDS1C approval, with a planned event in June 2025 signaling commercialization push amid strong funding and clinical wins.[1][5] Trends like personalized medtech and needle-free pharma will propel it, especially as allergy cases surge globally.
Its influence could expand via platform tech into other injectables, solidifying disruption in emergency care—transforming a patient-founded idea into a market standard for those seconds from crisis.[2][5]
